Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Botulinum toxin type F is one of the seven antigenically distinct serotypes (A–G) of botulinum neurotoxins produced by the bacterium *Clostridium botulinum* and related species. Like other serotypes, it acts as a potent neurotoxin that blocks neuromuscular transmission by inhibiting acetylcholine release at the neuromuscular junction. Botulinum toxins achieve this effect by binding irreversibly to presynaptic cholinergic nerve terminals and cleaving specific proteins in the SNARE complex required for vesicle fusion and neurotransmitter release. Specifically, type F cleaves synaptobrevin (also known as VAMP), a key component of the SNARE complex[6][8]. This results in flaccid paralysis of affected muscles. While types A and B are most commonly used clinically, type F has been investigated for therapeutic applications such as spastic disorders and dystonias[1][8]. Type A is considered most potent, followed by types B and then F[8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on botulinum toxin type F.